|
Pharma Mar is a biopharmaceutical company focused on the research, development, production, and commercialization of bioactive products of marine origin for oncology. Founded in 1986, the company explores marine invertebrates to identify antitumor compounds, managing the entire process from discovery to formulation. Its business segments include the development of marine-derived anticancer drugs and the management of subsidiaries dedicated to the commercialization of these products in Europe and the development of RNA interference. The company serves patients with cancer and other serious diseases, with its approved medications reaching international markets through a network of partners. Pharma Mar maintains a subsidiary in Germany and operates internationally, leveraging a collection of marine invertebrate samples to drive its therapeutic platform. Summarised from the company's own disclosures, fiscal year ended Dec 2025 |
Industry Biotechnology | Homepage pharmamar.com |
| Sector Healthcare | IR page pharmamar.com/es | |
|
Tags
marine biotechnology, oncology, antitumor drugs, rna interference, marine invertebrates, biopharmaceuticals
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | € 1.16B |
| Market cap (USD) | $ 1.282B |
| P/E | 20.66 |
| PEG | 1.38 |
| P/BV | 4.63 |
| P/S | 5.31 |
| P/OCF | 18.65 |
| P/FCF | 24.86 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 32.6% |
| ROI | 26.1% |
| ROIC | 21.1% |
| Profit margin | 33.9% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 15.0% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | Yes |
| Diluting (TTM) | — |
| Debt/Equity | 14.1% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 91 |
| Quality score | 25.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 221.39M | 174.855M | 158.153M | 196.343M | 229.831M | 269.961M | 85.819M | 162.588M | 179.363M | 180.947M | 193.817M | 149.652M | 141.824M | 138.229M | 152.486M | 153.508M |
| Net profit | 74.986M | 26.125M | 1.137M | 49.356M | 92.859M | 137.262M | -11.397M | -5.552M | -26.763M | -24.108M | 6.563M | 13.095M | 11.133M | 3.725M | -1.373M | -12.332M |
| Free cash flow | 46.668M | -8.988M | -29.402M | 29.469M | 17.874M | 275.94M | -28.12M | — | — | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||
| Trade receivables (EUR) | — | 11.5M | 24.1M | 50.9M | 29.3M | 27.6M | 34.7M | 39.4M |
| ↳ YoY growth | +108.6% | +111.6% | -42.4% | -6.0% | +25.9% | +13.6% | ||
| ↳ 5y CAGR | +24.6% | +10.4% | ||||||
| Borrowings, current (EUR) | — | — | — | — | 13.1M | 12.8M | 3.35M | 3.02M |
| Borrowings, non-current (EUR) | — | — | — | — | 25.9M | 27M | 39.9M | 35.6M |
| Lease liabilities (EUR) | — | 3.4M | 3.62M | 3.74M | 3.62M | 3.81M | 9.33M | 12.2M |
| Cash and deposits (EUR) | 22.7M | 17.6M | 96.2M | 113M | 150M | 60M | 63.2M | 17.8M |
| Intangible assets (EUR) | — | 6.07M | 3.86M | 3.23M | 2.59M | 1.94M | 1M | 3.55M |
| Right-of-use assets (EUR) | — | 3.35M | 3.55M | 3.64M | 3.55M | 3.73M | 3.17M | 2.76M |
| Net debt (borrowings + leases - cash) (EUR) | — | — | — | — | -107M | -16.4M | -10.7M | 32.9M |
| Cash flow detail | ||||||||
| Operating cash flow (EUR) | — | -24.2M | 279M | 25.7M | 38.3M | -13.4M | 6.03M | 53.1M |
| Purchases of property, plant and equipment (EUR) | — | -3.96M | -3M | -7.8M | -8.85M | -16M | -15M | -6.46M |
| Change in receivables (cash effect) (EUR) | — | 16.5M | 12.6M | 26.8M | -21.6M | -1.78M | 7.32M | 4.99M |
| Change in inventories (cash effect) (EUR) | — | 2.42M | 3.03M | -1.4M | 17.2M | 11.5M | 12.7M | 2.13M |
| Change in payables (cash effect) (EUR) | — | -5.5M | -4.65M | -7.19M | -1.79M | -1.83M | -11.2M | 12.8M |
| Dividends paid (cash effect) (EUR) | — | 0.00 | -8.82M | -10.9M | -11.8M | -11.7M | -11.4M | -13.9M |
| Share buybacks (cash effect) (EUR) | — | -7.47M | -63.7M | -40.7M | -50.2M | -37.9M | -18.6M | -34.1M |
| Interest paid (cash effect) (EUR) | — | -2.32M | -3.12M | -3.37M | -2.38M | -2.42M | -2.47M | -887,000 |
| Income taxes paid (cash effect) (EUR) | — | 0.00 | -9.65M | -7.86M | 2.72M | 16.6M | 23.3M | -3.71M |
| Share-based compensation (EUR) | — | 265,000 | 274,000 | 339,000 | 393,000 | 297,000 | 0.00 | 320,000 |
| Operating cash flow before change in receivables (EUR) | — | -40.7M | 266M | -1.08M | 59.9M | -11.7M | -1.29M | 48.1M |
| Free cash flow (OCF - PPE - intangibles) (EUR) | — | -28.2M | 276M | 17.9M | 29.5M | -29.4M | -8.99M | 46.7M |
| Income detail | ||||||||
| Research and development expense (EUR) | — | 50.6M | 53.8M | 72.2M | 83.4M | 99.3M | 104M | 95.2M |
| ↳ 5y CAGR | +15.4% | +12.1% | ||||||
| Total comprehensive income (EUR) | — | -11.4M | 137M | 92.8M | 49.3M | 1.17M | 26.1M | 75M |
| Comprehensive income to owners (EUR) | — | -11.3M | 137M | 92.8M | 49.3M | 1.17M | 26.1M | 75M |
| Reported | Feb 26, 2021 | Feb 26, 2021 | Feb 26, 2021 | Feb 28, 2022 | Feb 28, 2024 | Feb 28, 2024 | Feb 28, 2025 | Feb 27, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpInside information and other relevant information filed with the CNMV, newest first, titles as filed, own-share transactions and liquidity-contract reports included. The link opens the filed document. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding PHARMA MAR, S.A.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.